On Tuesday, H.C. Wainwright maintained a Buy rating and a $5.00 price target on shares of Barinthus Biotherapeutics (NASDAQ:BRNS). The firm's endorsement follows the announcement that updated data from the Phase 2b HBV003 trial of VTP-300 for chronic hepatitis B (CHB) would be presented at The Liver Meeting 2024, hosted by the American Association for the Study of Liver Diseases (AASLD).
The HBV003 trial has successfully enrolled 121 subjects, focusing on those with HBsAg levels below 200 IU/mL. The study is exploring the effects of various dosing regimens of VTP-300 in combination with low-dose nivolumab. By the clinical data cut-off on October 8, 40 participants had reached Day 169, and the results were promising. Twenty-four of these participants were eligible for nucleos(t)ide analogue (NUC) discontinuation, which is a significant step in CHB treatment.
Furthermore, the trial witnessed eight subjects achieving HBsAg loss, with two occurrences after Day 169. Out of nine subjects who opted to discontinue NUCs, six managed to stay off the therapy, with five maintaining this status for over six months. Notably, two of these six subjects met the criteria for a functional cure, and another two seroconverted to HBsAb positivity, indicating a positive immune response.
The combination therapy of VTP-300 and low-dose nivolumab has been generally well-received, with no serious adverse events related to the treatment reported as of the data cut-off. The firm believes that these findings reinforce previous results, suggesting that VTP-300 could significantly lower HBsAg levels and potentially allow patients to discontinue NUC therapy.
Given these developments, H.C. Wainwright reaffirms its confidence in the potential of VTP-300 as part of a functional cure regimen for CHB. The reiterated $5.00 price target reflects the firm's optimistic outlook on the stock's performance.
In other recent news, Barinthus Biotherapeutics has seen significant developments in its clinical trials and corporate structure. Two key clinical trials, HBV003 and PCA001, focusing on treatments for chronic hepatitis B and prostate cancer respectively, have completed patient enrollment. The firm, H.C. Wainwright, maintained a positive stance on Barinthus Biotherapeutics shares, reiterating a Buy rating. This optimism is based on the progress of the HBV003 trial of VTP-300, a treatment for chronic hepatitis B.
Adding to the developments, the company has launched the Phase 1 AVALON trial for VTP-1000, an investigational immunotherapy for celiac disease. Furthermore, Barinthus Bio has undergone internal restructuring, promoting Graham Griffiths to Chief Operating Officer and welcoming Dr. Leon Hooftman as its new Chief Medical (TASE:PMCN) Officer. The company also announced a 25% workforce reduction, a move expected to extend its cash runway into the second quarter of 2026.
In terms of clinical trials, Barinthus Biotherapeutics reported mixed results from the APOLLO trial of VTP-200, a treatment for cervical lesions associated with high-risk HPV infections. H.C. Wainwright's analysis suggests that VTP-300 has the potential to be a key component in a functional cure regimen for chronic hepatitis B, given its ability to significantly lower HBsAg levels and allow for the discontinuation of other therapies.
InvestingPro Insights
While H.C. Wainwright maintains a bullish stance on Barinthus Biotherapeutics (NASDAQ:BRNS) with a $5.00 price target, recent market data from InvestingPro paints a more nuanced picture. The company's stock has experienced significant volatility, with a 40.19% decline in the past week and a 69.56% drop over the last year. Currently trading at $0.84, BRNS is just 20.13% of its 52-week high, suggesting substantial downward pressure.
InvestingPro Tips highlight that BRNS holds more cash than debt on its balance sheet, which could provide some financial flexibility as it advances its clinical trials. However, the company is quickly burning through cash, a common characteristic of biotech firms in the development stage. This cash burn rate is particularly relevant given that analysts do not anticipate profitability this year, as indicated by another InvestingPro Tip.
Despite the challenging market performance, the fair value estimates present an intriguing contrast. Analyst targets suggest a fair value of $7.00, while InvestingPro's fair value estimate stands at $1.56, both significantly higher than the current trading price. This discrepancy between market price and estimated value may be of interest to investors considering the potential upside if VTP-300 continues to show promise in clinical trials.
For readers interested in a deeper analysis, InvestingPro offers 13 additional tips for BRNS, providing a more comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.